To compare the effect of tacrolimus and pimecrolimus in white patch patients
Phase 4
- Conditions
- Health Condition 1: null- Vitiligo
- Registration Number
- CTRI/2014/08/004882
- Lead Sponsor
- TANVI SINGH BHADORIA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Less than 20 % body surface area involvement in patients with vitiligo
Patients having vitiligo not on any other treatment for last 4 weeks
Exclusion Criteria
Involvement of more than 20% body surface area in patients with vitiligo
Immunocompromised patients
History of skin cancers or lymph proliferative disorders
Pregnant or lactating women
Patients on any other treatment for last 4 weeks
Netherton syndrome
Drop outs from the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of topical tacrolimus 0.1% ointment and pimecrolimus 1% <br/ ><br> <br/ ><br>cream in vitiligo patientsTimepoint: To compare the efficacy of topical tacrolimus 0.1% ointment and pimecrolimus 1% <br/ ><br> <br/ ><br>cream in vitiligo patients
- Secondary Outcome Measures
Name Time Method To compare the safety of Tacrolimus 0.1% ointment and Pimecrolimus 1 %cream in vitiligoTimepoint: 6 months